MSLN and neoplasm: In a phase I study, the anti-MSLN antibody MMOT0530A radiolabeled with 89Zr- [50] demonstrated maximum tumor uptake four days’ post-injection (mean SUVmax of 13.1 (±7.5)), with uptake observed in at least one tumor lesion in all patients (range 1–8).